About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

AZD8330 First Time in Man in Patients With Advanced Malignancies

NCT00454090·3 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

AstraZeneca

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Cancer which is refractory to standard therapies, or no therapies exist;

You may not be if

Participated in radiotherapy, biological or chemotherapy within 21 days prior to study start;
Hasn't participated in investigation drug study within 30 days;
Brain metastases/spinal cord compression unless treated and stable,
Off steroids/anticonvulsants.

The record

StatusCompleted

PhasePhase 1

Taking part83

StartedMar 2007

UpdatedAug 24, 2011

Conditions

Where3

Research Site
Philadelphia, Pennsylvania, United States
Research Site
Houston, Texas, United States
Research Site
Oslo, Norway

Clareo Health | AZD8330 First Time in Man in Patients With Advanced Malignancies